Contractor shall provide for a predictive bartlett esophagus assay pbea which will identify the probability that a patient will develop esophageal cancer over a 5 year period.
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 36C26121D0108
- Awardee
-
Castle Biosciences, Inc. UEI JMKGWGQLA7X7
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Task orders
- 4 $22,500 obligated
Award facts
- Opportunity
-
- Q301--640-21-1-044-0005 Tissue Cypher Esophagus Assay Services - total value $1, 250. 000. 00 Pre-Solicitation · 36C26121Q0757 · Posted Jun 10, 2021
- Predictive Bartlett's Esophagus Assay (PDEA) Solicitation · Posted Aug 6, 2021
- Combined order value
- $22,500 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 1% used
- $3,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 has awarded a $3 million indefinite delivery contract to Castle Biosciences, Inc., a for-profit diagnostics company, to provide a Predictive Bartlett Esophagus Assay (PBEA). The PBEA is a screening tool that identifies the probability of a patient developing esophageal cancer over a 5-year period. Under this IDV, the VA has issued multiple firm fixed-price delivery orders ranging from $12,500 to $125,000 for Castle Biosciences to deliver the PBEA service. Performance locations have included Friendswood, Texas; Palo Alto, California; and Blawnox, Pennsylvania. The IDV was originally solicited as a sole source award to Cernostics, Inc. in June 2021, but the VA determined Castle Biosciences could also meet the requirements. This contract supports the VA's efforts to address cancer risks and provide care for veterans within VISN 21's integrated network.
In addition to the PBEA IDV, Castle Biosciences holds a Federal Supply Schedule contract valued up to $3.6 million for its DecisionDx-Melanoma test through August 2026, as well as a separate $500,000 VA IDV for DecisionDx-Melanoma testing through July 2024. These contract vehicles allow the VA to access Castle Biosciences' cancer testing services to support veteran care across its healthcare system.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Novation Agreement | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36C26121D0108?
36C26121D0108 was awarded to Castle Biosciences, Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on September 15, 2021.
How much is contract 36C26121D0108 worth?
Orders under 36C26121D0108 have obligated $22,500. 36C26121D0108's own ceiling is $3,000,000.
How many orders have been placed under contract 36C26121D0108?
4 orders have been placed under 36C26121D0108, the latest on October 1, 2024.
Who can order from contract 36C26121D0108?
36C26121D0108 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 36C26121D0108 competed?
The extent of competition for 36C26121D0108 was not competed under sap. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV